Google DeepMind released AlphaGenome 2 on November 11, 2026, an AI model that predicts how a single DNA variant behaves differently depending on which type of cell it sits in. That sounds narrow, but it solves a problem that has slowed disease research for years: knowing that a gene variant is linked to a disease is one thing, knowing which of the body's hundreds of cell types it actually disrupts is another, and until now that second step mostly happened through slow, expensive lab work.
What the model actually does
AlphaGenome 2 takes a DNA sequence up to one million letters long and predicts how it gets read differently across different human cell types, including gene expression levels, chromatin accessibility, histone modification, and, new in this version, DNA methylation patterns. It was trained on more than 100 million single-cell profiles spanning 68 tissues, using data partly drawn from the Human Cell Atlas research consortium, plus both human and mouse genomes.
The practical use case: a researcher studying a disease-linked variant can ask the model which specific cell type the variant actually disrupts, instead of running that experiment physically in a lab across dozens of cell types first.
The benchmark numbers, with the actual comparison
DeepMind tested the new model against its 2025 predecessor using the TenK10K dataset, which covers 28 immune cell types. The results are a real jump, not a marginal one:
- AlphaGenome 2 correctly identified causal variants in 30% of cases, versus 16% for the original AlphaGenome.
- It predicted the correct direction of a gene's effect, whether activity goes up or down, 43% of the time, versus 23% for the original.
- It identified nearly twice as many expression-altering variants overall compared to its predecessor.
In one specific example DeepMind highlighted, the model showed that a DNA variant linked to COVID-19 risk disrupts gene activity much more strongly in T cells that have been activated by vaccination than in resting T cells, the kind of cell-specific detail that older, cell-blind models could not surface.
Why "research tool" is not a throwaway disclaimer
DeepMind is explicit that AlphaGenome 2 has not been validated or approved for clinical or diagnostic use. It is not a tool a doctor can plug a patient's DNA into and get a diagnosis out of. It is built for researchers trying to narrow down which cell types and mechanisms to investigate further, and that still has to be confirmed with wet-lab experiments before any of it reaches a clinic.
That distinction matters because it is exactly where AI health headlines tend to get overstated. A model that is nearly twice as accurate at a narrow prediction task is genuinely useful to the people doing that research, but it is not the same claim as "AI can now detect your disease risk," and DeepMind did not make that claim.
Access is split, and that is deliberate
The AlphaGenome API is open for non-commercial research use now. Commercial access, the kind a biotech or pharma company would need to build the model into a product pipeline, is still in private preview. DeepMind also said researchers who submit a specific use case by the end of November may get extra compute quota and credits, which suggests the team is still trying to learn what people actually want to do with it before opening it up more broadly.
The model also needs meaningfully more computing power to run than its predecessor, which is its own quiet signal: this kind of narrow, deeply specialized scientific AI is getting more capable at the same time it is getting more expensive to operate, a pattern showing up across the AI research world, not just at DeepMind.
The takeaway
AlphaGenome 2 is a good reminder that not every meaningful AI release looks like a flashy chatbot update. A model that moves a benchmark from 23% to 43% accuracy on predicting gene effects will not trend on social media, but it can genuinely shorten the path between finding a suspicious DNA variant and knowing which cell type to study next. The honest version of this story is also the less exciting one: this is a better microscope, not a cure, and DeepMind is saying so itself.